Geneva, June 22 -- International Clinical Trials Registry received information related to the study (NCT07645820) titled 'Evaluation of a Non-Invasive Device for Early Detection of Atopic Dermatitis Flares' on June 9.
Study Type: Observational
Primary Sponsor: Castle Biosciences Incorporated
Condition:
Atopic Dermatitis
Intervention:
Device: Nevisense electrical impedance spectroscopy
Recruitment Status: Recruiting
Date of First Enrollment: May 29, 2026
Target Sample Size: 450
Countries of Recruitment:
United States
To know more, visit https://clinicaltrials.gov/study/NCT07645820
Published by HT Digital Content Services with permission from Health Daily Digest....